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Abstract
Background: Cancer is the leading cause of death in older dogs and its prevalence is increasing. There is clearly a
need to develop more effective anti-cancer drugs in dogs. SG2000 (SJG-136) is a sequence selective DNA minor
groove cross-linking agent. Based on its in vitro potency, the spectrum of in vivo and clinical activity against human
tumours, and its tolerability in human patients, SG2000 has potential as a novel therapeutic against spontaneously
occurring canine malignancies.
Results: In vitro cytotoxicity was assessed using SRB and MTT assays, and in vivo activity was assessed using canine
tumour xenografts. DNA interstrand cross-linking (ICL) was determined using a modification of the single cell gel
electrophoresis (comet) assay. Effects on cell cycle distribution were assessed by flow cytometry and measurement
of γ-H2AX by immunofluorescence and immunohistochemistry.
SG2000 had a multi-log differential cytotoxic profile against a panel of 12 canine tumour cell lines representing a
range of common tumour types in dogs. In the CMeC-1 melanoma cell line, DNA ICLs increased linearly with dose
following a 1 h treatment. Peak ICL was achieved within 1 h and no removal was observed over 48 h. A
relationship between DNA ICL formation and cytotoxicity was observed across cell lines. The formation of
γ-H2AX foci was slow, becoming evident after 4 h and reaching a peak at 24 h.
SG2000 exhibited significant anti-tumour activity against two canine melanoma tumour models in vivo. Anti-tumour
activity was observed at 0.15 and 0.3 mg/kg given i.v. either once, or weekly x 3. Dose-dependent DNA ICL was
observed in tumours (and to a lower level in peripheral blood mononuclear cells) at 2 h and persisted at 24 h. ICL
increased following the second and third doses in a repeated dose schedule. At 24 h, dose dependent γ-H2AX foci
were more numerous than at 2 h, and greater in tumours than in peripheral blood mononuclear cells. SG2000-induced
H2AX phosphorylation measured by immunohistochemistry showed good correspondence, but less sensitivity, than
measurement of foci.
Conclusions: SG2000 displayed potent activity in vitro against canine cancer cell lines as a result of the formation and
persistence of DNA ICLs. SG2000 also had significant in vivo antitumour activity against canine melanoma xenografts,
and the comet and γ-H2AX foci methods were relevant pharmacodynamic assays. The clinical testing of SG2000
against spontaneous canine cancer is warranted.
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Background
Cancer is the leading cause of death in older dogs and
its prevalence is increasing [1, 2]. The skin and soft tis-
sues are common sites for tumour development with
mast cell tumours being the most common malignant
skin tumour. Mammary tumours and haematological
malignancies are also frequently diagnosed [3]. Current
therapies in canine oncology, including chemotherapy,
are often extrapolated from those known to be effective
in the corresponding human disease. There are currently
few veterinary licenced drugs for the treatment of cancer
in dogs. Although chemo-sensitive tumours can be
treated successfully initially, when conventional treat-
ment fails, few alternative options exist. In addition,
some types of tumours are intrinsically drug resistant
(e.g. malignant melanoma and many carcinomas). There
is clearly a need to develop novel effective agents with
an acceptable toxicity profile targeted towards the most
common canine malignancies.
SG2000 (SJG-136, NSC694501) is a rationally designed
pyrrolobenzodiazepine dimer which interacts sequence
selectively in the minor groove of DNA [4, 5]. It spans
six base pairs with a preference for 5’-purine-GATC-pyr-
imidine sequences, binding covalently to the N2-positions
of guanine on opposite strands of the DNA molecule to
form highly cytotoxic DNA interstrand cross-links (ICLs)
spanning four base pairs [5–7]. It can also form intras-
trand cross-links and monoadducts [8] and the ratio of
the three types of adducts can depend on sequence [9].
SG2000 was found to have potent multi-log differential
activity in the National Cancer Institute anticancer drug
screen with a mean GI50 (dose of SG2000 which gives
50 % inhibition of cell growth) of 7.4 nM (range 0.14 to
320 nM) [7]. The NCI standard COMPARE and molecu-
lar target analysis of the screening data suggested that
the drug had a distinct mechanism of action since, al-
though it had some similarity to other DNA binding
agents, it did not fit within the clusters of known
agents [7]. Based on these impressive in vitro data
and significant activity in the NCI standard hollow
fiber assay [7], SG2000 was tested extensively in vivo
against human tumour xenografts [7, 10]. In ten
tumour models tested by the NCI (including melan-
oma, breast, colon, lung and ovarian carcinomas,
brain tumours and leukemia), SG2000 was active
against small (150 mg) and large (250-400 mg) xeno-
grafts with tumour mass reductions in all ten models
[10]. Pharmacokinetic studies in rats [11] and dogs
[12] also reported peak plasma concentrations follow-
ing a single dose of SG2000 within the range of con-
centrations associated with in vitro DNA ICL and
anti-proliferative activity.
Based on the large body of data showing activity and
tolerability in preclinical studies, SG2000 entered clinical
Phase I testing in humans against both solid tumours
and haematological malignancies. Results from three of
these studies using different dosing schedules have been
reported [13–15] and the agent has progressed to human
Phase II clinical trials. Dose limiting toxicities included
edema, dyspnea, fatigue and delayed liver toxicity. No sig-
nificant myelotoxicity was observed. The in vitro potency,
alongside the tolerability and broad spectrum activity of
SG2000 against human tumours in vivo (with breast car-
cinoma, melanoma and haematological malignancies
being amongst the most sensitive), suggests that this
agent is a promising candidate as a novel cancer thera-
peutic against spontaneously occurring malignancies in
dogs. The current study was therefore undertaken to in-
vestigate the activity and cellular pharmacology of SG2000
in canine cancers in vitro, to assess the in vivo antitumour
activity of SG2000 against canine tumour xenografts and
to evaluate the potential of the comet and γ-H2AX foci
methods as pharmacodynamic assays for use in the fur-
ther clinical development of the drug.
Methods
Canine cell lines
CMeC-1, CMeC-2, KMeC, LMeC melanoma cell lines [16]
were provided by Professor Nobuo Sasaki (University of
Tokyo); the DEN haemangiosarcoma cell line [17] by
Professor Douglas Thamm (Colorado State University);
the melanoma 12 cell line [18] by Professor Michael
Kent (University of California, Davis). The ARCE mast
cell tumour line was provided by Dr Richard Elders
(formerly RVC, University of London, now at University of
Edinburgh). The canine cell lines C2, DH82, A72, D17,
CF33MG, CF35MG and MDCK and the human melanoma
cell line LOXIMVI, were obtained from ATCC.
Cell culture
Cell cultures were maintained in exponential growth with
the appropriate supplemented media in 75 mL cell culture
flasks, at 37 °C and 5 % CO2, in a humidified atmosphere.
EMEM (Eagle’s Minimal Essential Medium), DMEM
(Dulbecco Modified Eagle Medium) and RPMI (Royal
Park Memorial Institute) (PAA Laboratories GmbH, UK)
media were supplemented with heat inactivated foetal calf
serum (FCS), (Source BioScience, UK), glutamine (Source
BioScience, UK) and non-essential amino acids (NEAA)
(Source BioScience, UK), as required for the individual cell
lines as shown in Additional file 1: Table S1.
Drug
Pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2000 (SJG-
136, BN2629, NSC694501) was obtained from Ipsen Ltd,
(Slough, UK) in powder form and dissolved in dimethyl-
sulfoxide (DMSO) (Sigma-Aldrich Co, UK) to provide a
10 mM stock solution, stored at -20 °C. Further dilutions
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of SG2000 were prepared fresh from this stock in cell
culture medium to provide the desired concentration.
Cell growth inhibition assays
In vitro growth inhibition of SG2000 was assessed using
either the sulphorhodamine B (SRB) assay for adherent
cell lines or the methyl-3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay for suspen-
sion cell lines as previously described [7]. SG2000 was
used at a concentration range of 0.03 nM to 1000 nM.
Cytotoxic effects of SG2000 were measured either after
1 h (followed by 96 h in drug-free medium) or following
continuous (96 h) exposure and the GI50 dose was deter-
mined for each cell line. All chemicals were obtained
from Sigma-Aldrich (Poole, UK) unless specified.
Determination of DNA interstrand cross-link formation
and its repair using the single cell gel electrophoresis
(comet) assay
The details of the single cell gel electrophoresis (comet)
assay used to measure DNA ICL formation and repair are
described in detail elsewhere [19]. All procedures were
carried out on ice and in subdued lighting. Chemicals
were obtained from Sigma-Aldrich Co. (Poole, U.K.)
unless otherwise stated. Immediately before analysis
cells were diluted to give a final concentration of 2.5 ×104
cells/mL and irradiated (15 Gy) in order to deliver a fixed
number of random DNA strand breaks. After embedding
cells in 1 % agarose on a pre-coated microscope slide, the
cells were lysed for 1 h in lysis buffer (100 mM disodium
EDTA, 2.5 M NaCl, 10 mM Tris–HCl pH 10.5) containing
1 % Triton X-100 added immediately before analysis, and
then washed every 15 min in distilled water for 1 h. Slides
were then incubated in alkali buffer (50 mM NaOH,
1 mM disodium EDTA, pH12.5) for 45 min followed
by electrophoresis in the same buffer for 25 min at
18 V (0.6 V/cm), 250 mA. The slides were rinsed in neu-
tralising buffer (0.5 M Tris–HCl, pH 7.5) then saline.
After drying, the slides were stained with propidium
iodide (2.5 μg/mL) for 30 min then rinsed in distilled
water. Images were visualised using a NIKON inverted
microscope with high-pressure mercury light source, 510-
560 nm excitation filter and 590 nm barrier filter at ×20
magnification. Images were captured using an on-line
CCD camera and analysed using Komet Analysis software
6.0 (Andor Technology, U.K.). For each duplicate slide, 25
cells were analysed. The tail moment for each image was
calculated as the product of the percentage DNA in the
comet tail and the distance between the means of the head
and tail distributions [20]. DNA interstrand cross-linking
was expressed as percentage decrease in tail moment
compared to irradiated controls calculated by the formula:
% decrease in tail moment ¼ 1− TMdi−TMcuð ÞTMci−TMcuð Þ
 h i
 100
Where TMdi = tail moment of drug-treated irradiated
sample; TMcu = tail moment of untreated, unirradiated
control; TMci = tail moment of untreated, irradiated
control.
Measurement of SG2000-induced cell cycle alterations
using flow cytometry
Exponentially growing cells (2×106cells/mL) were
seeded in 6 well plates and incubated at 37 °C in 5 %
CO2 overnight. Cells were treated with SG2000 (GI50
dose) for 1 h and subsequently incubated for up to
72 h in drug free media; untreated cells were used as
controls. SG2000-treated cells and corresponding un-
treated controls were harvested by trypsinisation at
specific times post-incubation. Cells were pelleted at
200 g for 15 min at 4 °C, washed with cold phos-
phate buffered saline (PBS), centrifuged and fixed
with ice cold 70 % ethanol added drop-wise (samples
could be kept at -20 °C for up to 1 week).
Ethanol was removed from fixed samples by centrifu-
gation at 200 g for 5 min at 4 °C and cells were re-
suspended in 400 μL of propidium iodide (PI) staining
solution (0.05 mg/ml of PI, 0.5 mg/ml of RNAse A and
PBS, to a volume of 5 mL). Samples were incubated for
45 min at 37 °C in the dark and processed on a CyAn ADP
High-Performance Flow Cytometer (Beckman Coulter,
High Wycombe, UK). Gates were drawn to quantify
single cells and eliminate debris and doublets (clumped
cells). All reagents were obtained from Sigma-Aldrich Co.
unless stated.
Analysis of the red fluorescence from PI nuclear stain-
ing was performed using Summit 4.3 software (Dako
Colorado Inc. Colorado, USA) to quantify the percent-
age of cells in each phase of the cell cycle.
Measurement of γ-H2AX foci in vitro by
immunofluorescence
For in vitro studies, exponentially growing cells (2 × 104
cells/well) were seeded overnight in Nunc™ Lab-Tek™
chamber slides and incubated in a humidified atmosphere
at 37 °C and 5 % CO2. Cells were treated with SG2000 (0.1,
1, 10, 100 nM) at 37 °C and 5 % CO2 for 1 h and then fixed
after the appropriate post-incubation time with 1 mL of
ice-cold methanol-acetone 50:50 (VWR International,
UK) for 8 min at 4 °C. Cells were washed twice with cold
PBS and permeabilised (0.5 % Triton-X in PBS) for 15 min
at room temperature. Permeabilisation buffer was re-
placed with 1 mL of cold blocking buffer (0.1 % Triton-X,
0.2 % skimmed dry milk in PBS) at 4 °C overnight. Block-
ing buffer was washed 3 times with cold PBS and cells
were subsequently incubated with 500uL of primary
mouse monoclonal antibody anti-phospho-histone H2AX
(Ser139) clone JBW301 (Millipore (UK) Ltd, UK) (1:1000
dilution in blocking buffer) overnight at 4 °C. Unbound
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primary antibody was removed by washing three times for
5 min with washing buffer (0.1 % Triton-X in PBS) and
cells were incubated with Alexa Fluor® 488 goat anti-
mouse secondary antibody (Life Technologies UK) (1:1000
dilution in blocking buffer) for 4 h at room temperature
in the dark. Unbound secondary antibody was re-
moved by washing three times with washing buffer
for 5 min and the nuclei were counterstained with PI
(2 μg/mL) for 2 min in the dark. Slides were sepa-
rated from the chambers, rinsed with distilled water
for 30 min and allowed to dry in the dark. Slides were
mounted with Vectashield (Vector Laboratories, Peterbor-
ough, UK), a cover slip (25×60 mm, VWR inter-
national, Leicestershire, UK) and the edges of the
coverslip sealed with clear nail polish.
Images were visualised with an Axiovert Zeiss Micro-
scope equipped with Perkin Elmer Spinning Disc Tech-
nology with two channels (488 nm and 514 nm lasers)
and CCD camera (Perkin Elmer, UK) using a 63× oil
immersion objective. Nuclear foci were counted in 50 cells
per time point and results were expressed as mean num-
ber of foci per cell (mean ± SEM) from three independent
experiments with Velocity™ Acquisition/Visualisation soft-
ware (Perkin Elmer, UK).
In vivo studies
All animal experiments were performed in accordance
with the UK Home Office Animals Scientific Procedures
Act 1986, and United Kingdom Co-ordinating Commit-
tee on Cancer Research Guidelines for the Welfare and
Use of Animals in Cancer Research [21].
Subcutaneous tumour xenografts were established in
CD1 Nu/Nu immunocompromised female mice (Animal
Production Facility at the Royal Free Hospital, London)
for subsequent therapy and pharmacodynamic (PD) stud-
ies. A homogenous suspension of 5 × 106 exponentially
growing canine melanoma cells in serum free RPMI 1640
tissue culture medium was injected subcutaneously into
the right flank.
Once the xenografts were established, the mice were
divided into five groups of ten mice, with equivalent
mean tumour volumes for each group. SG2000 was
given intravenously into the tail vein to four of these
groups and vehicle control was administered to the fifth
group. Six mice in each group were used for the study of
the anti-tumour effect; tumour and body weight mea-
surements were taken every 3-4 days throughout the
study. The remaining four mice in the group were
used for the measurement of SG2000-induced phar-
macodynamic (PD) endpoints: DNA ICL formation
and γ-H2AX foci/cell, in peripheral blood mono-
nuclear cells and tumour tissue. These PD endpoints
were measured 2 and 24 h following SG2000 injec-
tion. These time points were chosen to capture the
peak of ICL and γ-H2AX, respectively, as determined
from in vitro experiments.
Tumours were measured every 3-4 days with digital
calipers until tumour masses reached a maximum size of
1.5 cm3. The greatest longitudinal diameter (length),
transverse diameter (width) and depth were measured to
calculate the tumour volume using the formula for an
ellipsoid in cm3 [22].
SG2000 dosing
SG2000 injections were prepared in 0.9 % NaCl and
1 % DMSO vehicle. Animals were weighed prior to
the injection to determine the volume of SG2000 re-
quired (0.1 mL/10 g body weight) which was given IV
in the tail vein. Control group mice were given an IV
injection of the vehicle solution; mice in groups one
and two were given a single treatment of SG2000,
0.15 mg/kg and 0.30 mg/kg respectively; mice in
groups four and five were given 0.15 mg/kg and
0.30 mg/kg respectively, every seven days for a total
of three treatments. These dosing strategies have been
used previously with SG2000 [7, 10].
Tumour tissue sampling for pharmacodynamics studies
Subcutaneously growing tumour xenografts were dis-
sected with a sharp scalpel blade and kept in cold RPMI
1640 media for immediate processing. Within 30 min, the
collected sample was placed in a petri dish over ice.
Tumour tissue was finely cut with scalpels, using a cross
cutting action, to achieve a single cell suspension. The cell
suspension was transferred to a falcon tube containing
5 mL of cold RPMI 1640 media and centrifuged at 200 g
for 5 min at 4 °C. The pellet was re-suspended in freezing
media (FCS containing 10 % DMSO) and stored at -80 °C.
Isolation of peripheral blood mononuclear cells from
peripheral blood (Ficoll technique)
Blood was collected from the heart by cardiac puncture
or from the tail vein by capillarity. Within 30 min of col-
lection, 100 μL blood was layered carefully onto 500 μL
of Ficoll-Paque TM Plus (GE Healthcare Bioscience, UK)
in an Eppendorf tube inside a 25 mL universal tube.
Blood samples were centrifuged at 450 g for 20 min at
room temperature allowing the centrifuge to stop with-
out using the brake. The fluffy mononuclear layer was
carefully removed using a Pasteur pipette and the vol-
ume made up to 5 mL with cold RPMI 1640 media in a
15 mL Falcon tube. Peripheral blood mononuclear cells
were centrifuged at 200 g for 5 min at 4 °C and the pel-
let was re-suspended in freezing media and stored at
-80 °C prior to analysis.
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Measurement of γ-H2AX foci in tumour cells and peripheral
blood mononuclear cells by immunofluorescence
Tumour cells and peripheral blood mononuclear cells
were fixed in suspension prior to adhesion to the slide.
Samples were thawed on ice, re-suspended in 5 mL of
cold PBS and centrifuged at 430 g for 5 min at room
temperature. Cells were fixed with 2 % paraformalde-
hyde (PFA) in PBS at room temperature for 20 min. Fol-
lowing centrifugation at 430 g for 5 min, the supernatant
was discarded and the cell pellet resuspended in 1 mL
PBS. The centrifugation step was repeated as above, the
supernatant discarded and the cell pellet re-suspended in
1 mL 70 % ice cold ethanol and incubated on ice for
10 min. The cells were centrifuged at 430 g for 5 min, the
supernatant discarded and the cell pellet re-suspended
in 200 μL ice cold ethanol. The cells were then trans-
ferred to a Shandon EZ single cytofunnel and centri-
fuged at 47 g with low acceleration for 5 min at
room temperature. The slides were removed and
allowed to dry at room temperature. Cells were
washed twice with cold PBS and permeabilised (0.5 %
triton-X in PBS) for 15 min at room temperature
followed by blocking (0.1 % triton-X, 0.2 % skimmed
milk powder in PBS) overnight at 4 °C. The cells
were washed three times with cold PBS and cells
were subsequently incubated with mouse monoclonal
antibody anti-phospho-histone H2A.X (Ser139) clone
JBW301 biotin-conjugated monoclonal primary anti-
body (Millipore (UK) Ltd,, UK) (dilution 1:1000 in
blocking buffer) overnight at 4 °C. Unbound primary
antibody was removed by washing three times for
5 min with washing buffer (0.1 % Triton-X in PBS)
and cells were incubated with streptavidin conjugated
Alexa Fluor® 488 goat anti-mouse secondary antibody
(Life Technologies, UK) (1:1000 dilution in blocking
buffer) for 4 h at room temperature in the dark. Un-
bound secondary antibody was removed by washing
three times with washing buffer for 5 min and the
nuclei were counterstained with PI (2 μg/mL) for 2 min in
the dark. Slides were mounted with Vectashield (Vector
Laboratories, UK), and the edges of the coverslip sealed
with clear nail polish.
Measurement of γ-H2AX in tumour tissue by
immunohistochemistry
Dissected tissue was fixed by complete immersion in a
10 % formalin solution for 24 h at room temperature.
Formalin-fixed paraffin wax-embedded tumour xeno-
graft tissues were sectioned with an AO rotary micro-
tome (RM2125 RTS, Leica Microsystems, Milton
Keynes, UK). Mounted slides were allowed to dry on a
slide warmer at 35 °C for 30 min followed by placing in
a dry oven at 100 °C overnight.
Tumour tissue sections on slides were de-waxed in
histoclear (National Diagnostics, Hull, UK) for 15 min
and dehydrated, first with 100 % IMS (industrial methyl-
ated spirits) and subsequently with 70 % IMS/H2O, for
15 min. Endogenous peroxidase activity was blocked
with 3 % H2O2/PBS for 20 min. Slides were washed in
PBS and antigen retrieval was achieved using 10 mM cit-
rate buffer (3.84 g citric acid in 2 L of H2O and addition
of sufficient 2 M NaOH to give pH 6) at full microwave
power (800 W) for 30 min. Non-specific binding was
blocked with 3 % normal goat serum for 20 min at room
temperature and incubated with mouse monoclonal
antibody anti-phospho-histone H2A.X (Ser139) clone
JBW301 (Millipore (UK) Ltd, UK)(dilution 1:200 in 3 %
normal goat serum) for 1 h at room temperature. Excess
antibody was removed by washing the sections three
times each for 5 min with PBS. Anti-antibody γ-H2AX
bound to the sections was incubated with Vectastain
avidin-biotin peroxidase complex (ABC) reagent (Vector
Laboratories, UK) for 30 min at room temperature. The
sections were subsequently washed three times for
15 min with PBS and peroxidase activity was visualised
by the formation of a brown product following addition
of labelled polymer-horseradish peroxidase (HRP) diami-
nobenzidine tetrahydrochloride (DAB) (Sigma, UK) for 5
min. Slides were washed with PBS for 15 min and coun-
terstained with hematoxylin (Harris) (Thermo Scientific)
for one minute. Sections were hydrated with 70 % IMS /
H2O, followed by 100 % IMS, cleared with histoclear for
15 min and mounted with a 50 × 24 mm coverslip and
DPX (VWR International).
Sections were visualised using an Axioskop bright
field microscope (Carl Zeiss Ltd. Hertfordshire, UK).
Images were captured by an AxioCam digital camera
and analysed with KS 300 image analysis software
(Carl Zeiss Ltd.).
Statistical analysis
Data were analysed using the GraphPad Prism 6.0 soft-
ware. Differences in the in vivo formation and persist-
ence of ICL in tumour tissue and peripheral blood
mononuclear cells following SG2000 treatment was
assessed by two-tailed Unpaired Students’ t-test. Differ-
ences in tumour growth and IHC markers between
groups were assessed by a 2-way ANOVA and multiple
t-tests. Spearman and Pearson correlations were also
used for IHC data. Results were considered as statisti-
cally significant at a p-value ≤0.05.
Results and Discussion
Activity of SG2000 against canine cell lines in vitro
The ability of SG2000 to cause growth inhibition in
twelve canine cancer cell lines, representing a range of
common tumour types in dogs, and two normal canine
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cell lines was assessed using the SRB assay (except for
the cell line C2 which grows partly in suspension and
was therefore determined using the MTT assay). Op-
timal growth conditions for the 14 cell lines were
established initially and are shown in Additional file
1: Table S1. The doubling time of the cells ranged
from 20 h (CF33) to 40 h (CMeC-1, CF35.Mg). Drug
exposure was either for 1 h or continuous (96 h).
GI50 values (dose of SG2000 which gives 50 % inhib-
ition of cell growth) are presented in Table 1. Com-
posite growth inhibition curves for all cell lines are
shown in Additional file 1: Figure S1.
SG2000 was cytotoxic across the panel of cell lines. A
multi-log differential cytotoxic profile was observed be-
tween tumour cell lines with GI50 values ranging from
0.33 - >100nM following a 1 h exposure, and <0.03 -
17.33nM following continuous exposure. The canine
tumour cell lines therefore showed a similar level of in
vitro sensitivity to human tumour cell lines, which gave
a mean GI50 of 7.4 nM in the NCI screen [7]. The two
normal cell lines gave GI50 values >100nM following a
1 h exposure and the MDCK normal kidney line was the
least sensitive cell line following continuous drug expos-
ure. The differential cytotoxicity between tumour cells
and normal cells therefore indicated a degree of selectiv-
ity for some cancer cells which has potentially important
implications clinically.
SG2000-induced DNA interstrand cross-link formation in
canine cell lines
DNA ICL formation was studied in canine tumour cell
lines following SG2000 treatment using the single cell
gel electrophoresis (comet) assay as previously described
[19]. Drug treatment was for 1 h and typical comet im-
ages are shown in Fig. 1a. It has been shown previously
in human tumour cell lines using the same methodology
that SG2000-induced DNA ICLs are formed rapidly
within 1 h of drug administration [7]. In the CMeC-1
cell line cross-linking (expressed as % decrease in tail
moment) was found to increase linearly with dose fol-
lowing a 1 h treatment over a dose range of 1-100nM
(Fig. 1b). The persistence of the cross-links over a 48 h
period was also examined following a 1 h exposure of
CMeC-1 cells to 53nM SG2000, the dose of drug which
gives 50 % decrease in tail moment (XL50). Fig. 1c shows
that the majority of ICL was achieved during the 1 h of
drug exposure and that no removal or unhooking of the
cross-links is observed over 48 h. This is consistent with
previous observations in human tumour cell lines [7].
The relationship between SG2000-induced DNA ICL
formation (XL50) and cytotoxicity (GI50) was examined
in six canine cancer cell lines (C2, ARCE, KMeC, LMeC,
CMeC-1 and CMeC-2) with differing sensitivities to
SG2000 and one human cancer cell line (LOXIMVI mel-
anoma). In Fig. 1d it can be seen that some relationship
between ICL formation and cytotoxicity exists (R2 =
0.7362). The cell line CMeC-2 is an outlier from the
other cell lines and if this cell line is excluded the R2
value becomes 0.9131. Although capable of producing
other types of DNA damage [8, 9], these data suggest
that the DNA ICL produced by SG2000 is a critical cyto-
toxic lesions.
Effect of SG2000 on the cell cycle in canine tumour cells
SG2000-induced cell cycle alterations were studied for
up to 72 h following a 1 h treatment at equi-toxic (GI50)
doses in four canine melanoma cell lines (CMeC-1,
CMeC-2, KMeC and LMeC). The percentage of cells in
G1/G0, S and G2/M are shown at 1, 4, 24, 48 and 72 h
in Fig. 2 for the four cell lines. Data exclude sub-G1
(apoptotic) cells, which constituted only a small percent-
age of cells at the doses used. For example, in CMeC-1
cells, apoptotic cells increased from 2.4 % at time 0 to
8.8 % at 72 h under the conditions employed. An overall
decrease in the number of cells in G1/G0 with time was
observed in all four cell lines. A clear increase in the
number of cells in G2/M was observed in the LMeC,
KMeC and CMeC-1 cell lines as has been observed
Table 1 Effect of SG2000 on the growth of canine cancer cells
and canine normal cells following a 1 h or continuous (96 h)
exposure
Cell Line Cell Type GI50 (nM)
a
1 h Continuous
C2 Mast cell 0.33 ± 0.84b <0.03b
ARCE Mast cell >100 4.10 ± 0.87
CMeC-1 Melanoma, cutaneous
(primary)
>100 17.33 ± 2.33
CMeC-2 Melanoma, cutaneous
(derived from CMeC-1,
metastatic in mouse model)
>100 11.0 ± 3.78
12 Melanoma, oral 63.63 ± 45 7.83 ± 1.16
KMeC Melanoma, oral 4.73 ± 2.22 <0.03
LMeC Melanoma, oral (metastatic
mandibular lymph node)
24.0 ± 3.21 1.60 ± 0.79
DH82 Monocyte/macrophage/histiocytic
sarcoma
>100 4.0 ± 2.0
A72 Connective tissue tumour 47.0 ± 3.51 0.83 ± 0.07
DEN Haemangiosarcoma 45.0 ± 2.5 0.75 ± 0.08
D17 Osteosarcoma 47.5 ± 2.5 0.92 ± 0.57
CF33MG Mammary gland carcinoma 9.0 ± 3.58 0.99 ± 0.01
CF35MG Mammary gland (normal) >100 6.0 ± 0.86
MDCK Kidney epithelial (normal) >100 28.33 ± 8.33
aGI50 values are the dose of drug required to inhibit growth by 50 %. Data
shown are the mean ± standard deviation from three
independent experiments
bData are from the SRB assay except for cell line C2 which grows partly in
suspension and where the GI50 value was determined using the MTT assay
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previously in human tumour cell lines [7, 23], indicating
that the drug induces cell cycle arrest at this stage of the
cell cycle. The exception, however, was cell line CMeC-2
which showed an accumulation of cells in S phase indi-
cating a different cell cycle arrest response in these cells.
It is interesting to note that this cell line did not give the
same relationship between cytotoxicity and cross-link
formation as the other cancer cell lines (Fig. 1d).
γ-H2AX foci formation following SG2000 treatment of
canine cancer cell lines
We have previously shown that exposure of cells to con-
ventional cross-linking agents and SG2000 can induce γ-
H2AX foci, clusters of modified histones formed at sites
of complex DNA damage [23–25]. In this study the re-
sponse to SG2000-induced DNA damage was investi-
gated by measuring SG2000-induced γ-H2AX foci in the
cutaneous (CMeC-1) and oral (LMeC) canine melanoma
cell lines. Cells were treated for 1 h with SG2000 and then
incubated for up to a further 48 h in drug-free medium.
Typical cell images showing the immunofluorescence
detection of γ-H2AX foci in CMeC-1 cells following a 1 h
exposure to 10nM SG2000 are shown in Fig. 3a. Foci were
scored compared to untreated controls and the time
course of formation in CMeC-1 cells is shown in Fig. 3b.
Despite cross-links forming rapidly within 1 h (Fig. 1c),
the γ-H2AX foci response is slow, only becoming evident
after 4 h and reaching a peak at 24 h, after which there is
a gradual decline up to 48 h.
The data clearly show that the γ-H2AX assay can detect
drug-induced DNA damage response at lower doses than
direct measurement of DNA ICL using the comet assay, as
we have shown previously [25]. Interestingly, the γ-H2AX
foci response to SG2000-induced DNA damage is markedly
different to conventional cross-linking drugs. We have pre-
viously shown that the peak of γ-H2AX foci formation is
approximately 1 h following the peak of ICL (measured
using the comet assay) for nitrogen mustard and platinum
drugs [24]. In the case of SG2000, however, the current
study in canine tumour cells shows that the γ-H2AX
response does not peak until 24 h after the peak of the
cross-linking. This is consistent with our previous findings
Fig. 1 Measurement of DNA interstrand cross-linking using the single cell gel electrophoresis (comet) assay. a. Typical comet images obtained
from CMeC-1 canine melanoma cells stained with propidium iodide following gel electrophoresis. a and b are untreated cells and c and d cells
treated with SG2000 for 1 h at 53 nM. Cells were either unirradiated (a,c) or irradiated with 15 Gy (b,d) prior to analysis. b. Dose-dependent
formation of DNA interstrand cross-linking in the CMeC-1 canine melanoma cell line immediately following a 1 h exposure to SG2000.
Results are expressed as the mean percentage decrease in the tail moment ± SEM of three independent experiments. c. Persistence of
SG2000-induced DNA ICLs in the canine melanoma cell line CMeC-1 following a 1 h treatment with SG2000 at 53 nM during 48 h of
post-incubation in drug-free medium. Results show the mean percentage decrease of the tail moment ± SEM from three independent
experiments. d. Relationship between SG2000-induced DNA ICL formation (XL50 - dose of SG2000 which gives 50 % decrease in tail moment) versus
cytotoxicity (GI50 - measured using the SRB assay (Table 1)) of six canine tumour cell lines (C2, ARCE, KMeC, LMeC, CMeC-1 and CMeC-2) and one
human melanoma cell line (LOXIMVI). Values represent the mean ± SEM from three independent experiments
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in human cells [25] and may reflect the non-distorting na-
ture of the cross-links produced by this agent [5, 7] which
may evade early detection by DNA damage response and
repair mechanisms.
The effect of dose of SG2000 on γ-H2AX response was
determined in both the CMeC-1 and LMeC cell lines
(Fig. 4). LMeC cells (Fig. 4b) showed a greater level of back-
ground γ-H2AX foci compared to CMeC-1 cells (Fig. 4a).
A clear dose response was observed in both cell lines, with
greater numbers of foci/cell in LMeC cells at all doses
tested (Fig. 4c). This is consistent with the increased sensi-
tivity of this cell line to SG2000. Despite the clear dose-
dependent effect, the response was heterogeneous in the
cell population at all doses as can be seen by the large
errors when the data are expressed as mean foci/cell
(Fig. 4c). This can be clearly seen from Fig. 4a and b where
in both cell lines at the highest dose of 100 nM there are
still >10 % cells which have less than 5 foci per cell. Since
γ-H2AX is probably marking sites of DNA double strand
breaks generated during lesion processing by structure
specific endonucleases, this heterogeneous response may
reflect cells in different phases of the cell cycle.
Efficacy of SG2000 against canine melanoma xenograft
tumours in vivo
Subcutaneous tumour xenografts in mice were used
to investigate whether the observed in vitro cytotoxic
activity of SG2000 in canine tumour cell lines trans-
lated into in vivo anti-tumour activity. Melanoma cell
lines were chosen for in vivo xenograft studies since
melanoma is a common canine tumour, constituting
7 % of all malignant neoplasms, and is the most com-
mon oral malignancy in dogs, being highly metastatic
from this site and resistant to most conventional chemo-
therapy agents [26]. CMeC-1 and LMeC cell lines
were selected, following the preliminary studies on
the four canine melanoma lines, due to their ability
to establish as subcutaneous tumours in CD1 Nu/Nu
immunocompromised mice. CMeC-1 was established
from a primary cutaneous melanoma and LMeC was
established from a metastatic mandibular lymph node
where the primary tumour originated in the oral cav-
ity. Cutaneous and oral melanomas usually have very
different biological behaviours in dogs, with the cuta-
neous form typically being behaviourally benign and
the oral form usually being highly malignant and
metastatic, therefore we might expect these two cell
lines to respond differently to therapy. In vitro LMeC
was approximately ten-fold more sensitive to SG2000
than CMeC-1 (GI50 values 1.6 nM and 17.33 nM
after 96 h exposure, respectively).
Data from in vivo efficacy experiments are shown in
Fig. 5 against LMeC (A,B) and CMeC-1 (C,D) tumours.
SG2000 was administered at two dose levels (0.15 mg/
kg and 0.3 mg/kg) using two dosing schedules: single
administration (Fig. 5a, c) and once weekly x 3 (Fig. 5b,
d). For LMeC, dose dependent inhibition of tumour
growth was observed with both dosing schedules, the
repeated dose schedule giving a significantly greater
growth delay (p < 0.05) which was >40 days at the dose
Fig. 2 SG2000-induced cell cycle alterations in four canine melanoma cell lines following a 1 h treatment with equitoxic (GI50) doses of SG2000
and 72 h of post-incubation. The doses used were LMeC 24nM, KMeC 4.7 nM, CMeC-1 1 μM and CMeC-2 300 nM. Values represent the
percentage of cells in the G1/G0 (black), S (white), and G2/M (grey) phases of the cell cycle according to DNA content per cell, assessed
by flow cytometry. The percentage of cells in each phase was calculated from a minimum of 10,000 events and the values shown represent the
mean from three independent experiments ± SEM
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of 0.3 mg/kg weekly × 3. Compared to the untreated
control group, the anti-tumour effect was significant in
all SG2000 dose schedules (p < 0.05), apart from the
0.15 mg/kg single dose (p = 0.14). Both mean and me-
dian survival was increased over the control group
under all treatment conditions (Additional file 1: Table
S2). Median percentage weight loss was 0 and 2.45 in
the single dose 0.15 and 0.3 mg/kg groups, respect-
ively, indicating that the drug was well tolerated under
this schedule. Median percentage weight loss of 1.9
and 15.81 was observed in the repeat dose 0.15 and
0.3 mg/kg groups, respectively, suggesting some tox-
icity at the higher dose level. Weight regain was, how-
ever, observed within 14 days following the final dose
of SG2000.
The CMeC-1 tumour grew more slowly in vivo in control
animals compared to LMeC. Significantly greater anti-
tumour effect (p < 0.01) was observed following the high
dose of SG2000 (0.30 mg/Kg) compared to the low dose
(0.15 mg/Kg), either as a single dose (Fig. 5c) or adminis-
tered once a week for three weeks (Fig. 5d). Similarly to
what was observed with LMeC, the three-week dose sched-
ule produced a better anti-tumour effect than the single
dose schedule (p < 0.05). Overall, the anti-tumour effect
was greater against the CMeC-1 tumour than the LMeC,
with growth delays >100 days at both doses in the repeated
dose schedule. An overall increased survival was observed
over controls in all schedules except for the single dose
0.15 mg/kg, with the mean survival increased by 90 days
over controls in the repeat dose 0.3 mg/kg group
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Fig. 3 a. Immunofluorescence detection of γH2AX phosphorylation in the canine melanoma CMeC-1 cell line following a 1 h treatment with 10
nM SG2000 and up to 48 h of post-incubation in drug-free medium. Immunofluorescence detection of phosphorylated H2AX (γH2AX) appears
as green foci. Cellular DNA was counter-stained red with propidium iodide. Representative cells are shown x 63 magnification. b. SG2000-induced
γH2AX foci/cell in the CMeC-1 canine melanoma cell line following a 1 h treatment with SG2000. Values represent the mean number of
γH2AX foci/cell (50 cells per experiment) ± SEM, from three independent experiments. Results were normalised with the mean γH2AX
foci/cell of untreated control cells
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(Additional file 1: Table S3). The drug was again well toler-
ated with no significant weight loss observed in the single
dose schedules. In the repeated dose schedules the median
percentage weight loss was 4.4 and 12.6 in the repeated
dose 0.15 mg/kg and 0.3 mg/kg groups, respectively, again
indicating some toxicity at the higher repeated dose.
SG2000 clearly exhibited significant anti-tumour activ-
ity against the two canine melanoma tumour models in
vivo. Greater activity was observed in CMeC-1 than in
LMeC, despite the latter being approximately ten times
more sensitive to the drug in vitro. This difference in
activity could relate to differences in growth rate of the
tumours in vivo, factors such as differences in tumour
architecture and vascularisation [27] or different oxygen-
ation of the tumour masses [28], thereby influencing the
delivery of SG2000 in the tumour microenvironment.
The reduced sensitivity of LMeC relative to CMeC-1 in
vivo is somewhat disappointing, since it is the highly
metastatic oral form of the disease for which effective
systemic drug treatment is sought. It is worth noting,
however, that CMeC-1 may not behave like a typical cu-
taneous melanoma of haired skin since it was metastatic
Fig. 4 SG2000-induced γH2AX foci/cell in a. CMeC-1 and b. LMeC cell lines following a 1 h treatment with SG2000 and 24 h post-incubation in
drug-free medium. Values shown represent the mean percentage distribution of γH2AX foci/cell (50 cells per experiment) from three independent
experiments. c. Mean number of foci/cell from CMeC-1 and LMeC cells following treatment for 1 h with SG2000 at the doses shown followed by
24 h post-incubation in drug-free medium. Values are the mean ± SEM from three independent experiments
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to the lymph node in the original patient [16] and may
therefore behave more like a subset of cutaneous mela-
nomas that behave aggressively. Nevertheless, SG2000
showed significant activity against both tumour models
in vivo and the anti-tumour activity in canine patients
with spontaneous tumours might be different to those
seen in xenograft models.
Pharmacodynamic measurement of SG2000-induced DNA
interstrand cross-linking
The formation of ICLs in vivo was determined using the
single cell gel electrophoresis (comet) assay at doses of
SG2000 shown in the above efficacy experiments to give
dose-dependent tumour growth inhibition. LMeC tu-
mours were taken after 2 h and 24 h following treatment
with 0.15 or 0.3 mg/kg SG2000 and the level of cross-
linking determined as the % decrease in tail moment
(% DTM, Fig. 6a). A high level of DNA cross-linking
was observed in tumour cells at 2 h, consistent with the
rapid formation of SG2000-induced cross-links observed
in the LMeC cell line in vitro. The level of cross-linking in
tumour was significantly greater at the higher dose of
0.3 mg/kg, consistent with the increased antitumour effect
observed at this dose (Fig. 5). At 24 h cross-links were still
evident in tumours at both dose levels (Fig. 6a), consistent
with the persistence of the cross-linking observed in vitro.
A similar experiment was performed in mice bearing
CMeC-1 tumours (Fig. 6b), however, additionally in these
experiments lymphocytes were also examined for DNA
ICL at the same time points as the tumour samples. Dose
dependent cross-linking at 2 h and persistence at 24 h was
again observed in this tumour in vivo. In addition, cross-
linking was also observed in lymphocytes, although at a
lower level than that observed in tumour cells. This again
suggests some degree of selectivity of SG2000 for tumour
cells over normal cells.
The measurement of cross-linking described above was
following a single administration of SG2000 to mice at
0.15 or 0.3 mg/kg. It is clear from Fig. 5, however, that en-
hanced antitumour activity is observed against both the
LMeC and CMeC-1 melanomas using a weekly repeat
dose schedule. The effect of repeated dosing on the level
of cross-linking was determined in peripheral blood
mononuclear cells since it is possible to take repeated
blood samples from the same mouse. It can clearly be seen
in Fig. 6c that the level of cross-linking increases following
the second and third doses of SG2000 suggesting that a
significant level of un-repaired cross-links are still present
from the previous drug administration at the time of sub-
sequent dosing. Such persistence of SG2000-induced
cross-links was observed in the Phase I study in humans
where DNA ICLs correlated with systemic exposure and
were still detectable immediately before cycle 2 [14].
Pharmacodynamic measurement of SG2000-induced
γ-H2AX DNA damage response
Despite SG2000-induced cross-links forming rapidly
within 1 h, the γ-H2AX foci response in vitro is slow,
reaching a peak at 24 h (Fig. 3b). This may reflect the
non-distorting nature of the cross-links produced by this
Fig. 5 SG2000-induced anti-tumour activity in LMeC (a,b) or CMeC-1 (c,d) canine melanoma tumour xenografts in CD1 Nu/Nu nude mice. a and
c are with a single dose of SG2000 i.v. at 0.15 mg/kg or 0.30 mg/kg compared to vehicle only controls. Median tumour volume (cm3) from six
mice per group is plotted against time in days. b and d are as in a and c but SG2000 is given one dose per week for three weeks i.v. at 0.15
mg/kg [●] or 0.30 mg/kg [♦]
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agent [5, 7] which may evade early detection by the cel-
lular DNA repair machinery. Aliquots of the same sam-
ples to those examined for DNA ICL in vivo (Fig. 6)
were examined for γ-H2AX foci response (Fig. 7). In
LMeC tumour cells (Fig. 7a) increased foci were observed
compared to untreated tumours at 2 h, with more foci at
0.3 mg/kg compared to 0.15 mg/kg. Consistent with what
we observed in canine cells in vitro and in previous studies
in both human cells in vitro and clinical samples [25], at
24 h the number of foci was much greater than at 2 h at
both dose levels. A similar dose and time response was
observed in CMeC-1 tumours (Fig. 7b).
The γ-H2AX foci response was also determined in per-
ipheral blood mononuclear cells taken at the same time
points as the tumours (Fig. 7). The background (control)
level of γ-H2AX foci was lower in peripheral blood mono-
nuclear cells than in tumour. Background levels of γ-H2AX
have been shown to vary widely between cells in different
tissues, culture or different cell lines and it has been found
that elevated levels of γ-H2AX are present in a number of
human cancer cell model systems [29, 30], suggesting that
an increased level of DNA damage is a general characteris-
tic of cancer development. The level of γ-H2AX foci follow-
ing SG2000 treatment was also greater in tumour than in
the corresponding peripheral blood mononuclear cells
(Fig. 7). This is consistent with what was observed with
DNA ICL in Fig. 6b, again suggesting some degree of se-
lectivity for cancer cells.
Measurement of SG2000-induced γ-H2AX phosphorylation
in tumour tissue using immunohistochemistry
SG2000-induced H2AX phosphorylation was measured
in formalin-fixed paraffin-embedded LMeC or CMeC-1
tumour tissue sections. The tumour samples were from
the same tumours used for comet and γ-H2AX foci as-
says. Typical immunohistochemistry images are shown
Fig. 6 SG2000-induced DNA interstrand cross-linking, expressed as the % decrease in comet tail moment (% DTM) in tumour cells (solid bars)
from mice carrying either a) LMeC or b) CMeC-1 subcutaneous xenografts. Samples were harvested at 2 and 24 h following treatment
with either 0.15 mg/kg or 0.30 mg/kg (single dose). Values are the mean % DTM ± SEM calculated from 50 tumour cells each, from three
mice each at each time point. In b) open bars are the % DTM in peripheral blood mononuclear cells taken at the same time points as
the CMeC-1 tumours. c. SG2000-induced DNA interstrand cross-linking in peripheral blood mononuclear cells from mice carrying LMeC
or CMeC-1 xenografts. Blood samples were harvested from at least three mice at 2 h and from at least three mice at 24 h, following
each of three once-weekly doses of SG2000 (either 0.15 mg/kg or 0.30 mg/kg). The % DTM was calculated from 50 cells in each sample
as described previously and data are the mean ± SEM. Statistical analysis: p ≤ 0.001 = ***, p ≤ 0.01 = **, p ≤ 0.05 = *, ns = not significant
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in Fig. 8a, and the number of γ-H2AX positive cells in
CMeC-1 and LMeC tumours shown in Fig. 8b.
In both tumour types, a greater number of γ-H2AX posi-
tive cells were measured at each time point following
0.30 mg/kg than following 0.15 mg/kg. At each dose, more
positive cells were present at 24 h than at two hours after
treatment with SG2000, and the effect was greater in
CMeC-1 than in LMeC. The number of γ-H2AX positive
cells two hours after treatment with 0.15 mg/kg of SG2000
was not significantly different to the number of γ-H2AX
positive cells in the untreated control sections. The number
of γ-H2AX positive cells 2 h after treatment with 0.3 mg/kg
of SG2000 was, however, significantly greater than in the
untreated control sections (p < 0.05). The number of γ-
H2AX positive cells 24 h after treatment with either
0.15 mg/kg or 0.30 mg/kg of SG2000 was significantly
greater than the number in the untreated control sections
(p < 0.05). This was observed in mice carrying either
CMeC-1 or LMeC tumour xenografts. These results indi-
cate overall numbers of γ-H2AX positive cells rather than
the intensity of staining in a cell, and this assay showed less
sensitivity than the γ-H2AX foci technique. However, the
data was in good correspondence with that obtained with
the latter technique.
Conclusions
SG2000 demonstrated a similar level of potent in vitro ac-
tivity against a panel of canine tumour cell lines as has been
previously demonstrated against human tumour cells.
Cytotoxicity correlates with the formation and persistence
of sequence selective ICLs in the DNA minor groove as
demonstrated using the single cell gel electrophoresis
(comet) assay. The cross-links result in a delayed, but ro-
bust, γ-H2AX foci response. SG2000 has significant in vivo
antitumour activity against canine melanoma tumour xeno-
grafts, and the comet and γ-H2AX foci methods are shown
to be relevant in vivo pharmacodynamic assays for measur-
ing DNA ICL and DNA damage response. The clinical test-
ing of SG2000 against canine cancer with associated
pharmacodynamic biomarker support is clearly warranted,
and a Phase I study in dogs with spontaneous malignancies
is currently underway and will be reported in due course.
Fig. 7 SG2000-induced γ-H2AX foci in tumour cells and peripheral blood mononuclear cells (lymphocytes) harvested from three mice carrying
subcutaneous a) LMeC or b) CMeC-1
canine melanoma xenograft tumours, at 2 and 24 h following either 0.15 or 0.3 mg/kg SG2000. γH2AX foci/cell were counted in the first 50 cells
and results were grouped in ranges (0, 1–5, 6–10, 11–15, 16–20, and >20 γ-H2AX foci/cell)
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Fig. 8 γ-H2AX peroxidase staining in paraffin-embedded tissues of canine melanoma xenografts following treatment with SG2000 (single
dose of 0.15 mg/Kg or 0.30 mg/Kg). Samples were harvested 2 h and 24 h after administration of the drug. a) Examples of fixed tissue
sections with γ-H2AX peroxidase staining from SG2000-treated CMeC-1 tumour compared to sections from untreated control mice (left).
All images are x20 magnification, except the bottom left image that is x10 magnification. b) Mean number of γ-H2AX positive cells ± SEM
per microscopic field (x 20 magnification) in samples from mice bearing either CMeC-1 (left) or LMeC (right) xenograft (sections from three mice were
examined in each case). To calculate the mean γ-H2AX value, at least 150 cells (at least 50 cells per mouse) and 20 fields per sample were counted.
Statistical analysis: p≤ 0.05 = *, ns = not significant
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Additional file
Additional file 1: Table S1. Specific culture media and supplements
required for optimum canine cell lines growth. EMEM - Eagle’s Minimal
Essential Medium, DMEM - Dulbecco’s Modified Eagle Medium, RPMI
- Royal Park Memorial Institute Medium, FBS – foetal bovine serum,
NEAA – non-essential amino acids. Table S2. The effect of SG2000
on the survival of LMeC xenografted mice following different SG2000
dosage regimes. Table S3. The effect of SG2000 on the survival of
CMeC-1 xenografted mice following different SG2000 dosage regimes.
Figure S1. In vitro cytotoxicity of SG2000 against 12 canine tumour
cell lines and two canine normal cell lines. Cell viability was assessed
using the SRB assay (except for cell line C2 which was assessed using
the MTT assay). Results shown are the mean (± SEM) calculated from three
independent experiments, expressed as a percentage absorbance at A540
nm compared to untreated control cells. A) 1 h exposure to SG2000
followed by 96 h post-incubation in drug-free medium. B) Continuous (96 h)
exposure to SG2000. (PDF 404 kb)
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